Combining Behavioral Treatment With Agonist Maintenance - 1

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000311

Purpose

The purpose of this study is to evaluate whether the community reinforcement approach (CRA) plus contingency management (CM) is more effective overall than CRA only in reducing illicit opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up after completion of study protocol, and to compare the efficacy of maintenance on buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM.

Condition	Intervention	Phase
Cocaine-Related Disorders Opioid-Related Disorders Substance-Related Disorders	Drug: Buprenorphine	Phase III

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Combining Behavioral Treatment With Agonist Maintenance

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Depression
Withdrawal symptoms
Opioid and cocaine use
Social and psychological functioning
AIDS risk behavior

Estimated Enrollment:	168
Study Start Date:	September 1999

Arms	Assigned Interventions
1: Experimental Therapeutic Contracting (TC)	Drug: Buprenorphine Experimental Therapeutic Contracting (TC) Experimental Cognitive Behavioral Coping Skills Therapy (CBT)
2: Experimental Cognitive Behavioral Coping Skills Therapy (CBT)	Drug: Buprenorphine Experimental Therapeutic Contracting (TC) Experimental Cognitive Behavioral Coping Skills Therapy (CBT)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000311

Locations

United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Richard Schottenfeld, M.D.

Yale University

More Information

Responsible Party:	Yale University School of Medicine ( Richard S. Schottenfeld, MD )
Study ID Numbers:	NIDA-09413-1, R01-09413-1
Study First Received:	September 20, 1999
Last Updated:	October 27, 2008
ClinicalTrials.gov Identifier:	NCT00000311
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Buprenorphine
Mental Disorders

Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

Additional relevant MeSH terms:

Disease
Physiological Effects of Drugs
Narcotic Antagonists
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Pathologic Processes

Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009